Pelage are starting phase 3 for PP405 towards the end of 2026
    Chat 2/11/2026

    From the encyclopedia
    PP405 →

    mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    Minoxidil →

    Vasodilator used on the scalp and, at low doses, as a tablet

    At a glance
    In this general discussion post, the primary subjects mentioned are
    💊 Minoxidil (oral)
    the tone is 😐 neutral with 31% of male patients experienced a 20% increase in hair density results.

    Other terms

    PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community What new hair-loss treatments actually look exciting right now (Oct 2025)

       171 upvotes 11 months ago
      New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

      community The future of hair loss drugs.

       34 upvotes 7 months ago
      Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

      community VDPHL01 phase-2/3 results comparison

      in Research/Science  128 upvotes 5 months ago
      The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

    Related Research

    6 / 6 results